IP Verse

Methods For Achieving Therapeutically Effective Doses Of Anti-Cd47 Agents - EP2970493

The patent EP2970493 was granted to The Board OF Trustees OF The Leland Stanford Junior University on Apr 3, 2019. The application was originally filed on Feb 26, 2014 under application number EP14768797A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2970493

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Application Number
EP14768797A
Filing Date
Feb 26, 2014
Status
Granted And Under Opposition
Mar 1, 2019
Publication Date
Apr 3, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENMABJan 3, 2020J A KEMPADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEJan 2, 2020KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2010239579
DESCRIPTIONUS2011014119
DESCRIPTIONUS2012282174
DESCRIPTIONWO2011143624
DESCRIPTIONWO2013109752
INTERNATIONAL-SEARCH-REPORTUS2007113297
INTERNATIONAL-SEARCH-REPORTUS2010239578
INTERNATIONAL-SEARCH-REPORTUS2010323949
INTERNATIONAL-SEARCH-REPORTUS2012282174
INTERNATIONAL-SEARCH-REPORTWO2011143624
INTERNATIONAL-SEARCH-REPORTWO2013109752
OPPOSITIONWO2011143624
OPPOSITIONWO2014108483
SEARCHUS2014140989

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- E C PIETSCH ET AL, "Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies", BLOOD CANCER JOURNAL, (20170224), vol. 7, no. 2, doi:10.1038/bcj.2017.7, page e536, XP055395279
OPPOSITION- CAMPBELL, I. G. et al., "An Ovarian Tumor Marker with Homology to Vaccinia Virus Contains an IgV-like Region and Multiple Transmembrane Domains", Cancer Research, (19920000), vol. 52, pages 5416 - 5420, XP055348255
OPPOSITION- "Chapter 33: Clinical manifestations and classification of erythrovyte disorders", (20100000), page 457
OPPOSITION- Kikuchi et al., "Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, (20090901), vol. 100, pages 311 - 317, XP027707307
OPPOSITION- KIKUCHI, Y. et al., Leuk. Res., (20050000), vol. 29, pages 445 - 450
OPPOSITION- POELS, L. G. et al., "Monoclonal Antibody Against Human Ovarian Tumor-Associated Antigens", J. Natl. Cancer Inst., (19865000), vol. 76, pages 781 - 791, XP055663185
OPPOSITION- RIZZO, J. D. et al., "Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update", J. Clin. Oncol., (20080000), vol. 26, no. 1, pages 132 - 149, XP055663390
OPPOSITION- FOSSATI-JIMACK, L. et al., "Selective Increase of Autoimmune Epitope Expression on Aged Erythrocytes in Mice: Implications in Anti-erythrocyte Autoimmune Responses", Journal of Autoimmunity, (20020200), vol. 18, no. 1, pages 17 - 25, XP055663371
OPPOSITION- KIKUCHI, Y. et al., "A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells", Biochem. Biophys. Res. Commun., (20040000), vol. 315, pages 912 - 918, XP004491573
OPPOSITION- OLSSON, M. et al., "Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes", Biochem. Biophys. Res. Commun., (20070000), vol. 352, no. 1, pages 193 - 197, XP005724581
OPPOSITION- MAJETI, R. et al., "CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", Cell, (20090000), vol. 138, pages 286 - 299, XP055277135
OPPOSITION- JAISWAL, S. et al., "CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis", Cell, (20090000), vol. 138, pages 271 - 285, XP009160236
OPPOSITION- CHAO, M. P. et al., "The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications", NIH Public Access Author Manuscript, (20120000), vol. 24, no. 2, pages 1 - 13, XP055663150
OPPOSITION- ANNISS, A. M. et al., "Expression of CD47 (integrin-associated protein) decreases on red blood cells during storage", Transfusion epsilont Apheresis Science, (20020000), vol. 27, no. 3, pages 233 - 238, XP055055464
OPPOSITION- MATEO, V. et al., "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia", Nat. Med., (19990000), vol. 5, pages 1277 - 1284, XP002163073
OPPOSITION- PIETSCH, E. C. et al., "Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies", Blood Cancer Journal, (20170000), vol. 7, pages 1 - 8, XP055395279
OPPOSITION- VALK, P. J. et al., "Prognostically useful gene-expression profiles in acute myeloid leukemia", N. Engl. J. Med., (20040000), vol. 350, pages 1617 - 1628, XP002361722
OPPOSITION- WILLINGHAM, S. B. et al., "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors", PNAS, (20120000), vol. 109, no. 17, pages 6662 - 6667, XP055302774
OPPOSITION- WILLINGHAM, S. B. et al., "Reply to Soto-Pantoja et al. and Zhao et al.: Targeting CD47 on human solid tumors", PNAS, (20120000), vol. 109, no. 42, pages E2844 - E2845, XP055663179
OPPOSITION- THEOCHARIDES, A. P. A. et al., "Disruption of SIRP signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts", J. Exp. Med., (20120000), vol. 209, no. 10, pages 1883 - 1899, XP055126663
OPPOSITION- SICK, E. et al., "CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest", British Journal of Pharmacology, (20120000), vol. 167, no. 7, pages 1415 - 1430, XP055247122
OPPOSITION- KHANDELWAL, S. et al., "Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation", Transfusion, (20070000), vol. 47, no. 9, pages 1725 - 1732, XP055663373
OPPOSITION- LUTEN, M. et al., "Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods.", Transfusion, (20080000), vol. 48, no. 7, pages 1478 - 1485, XP055663382
OPPOSITION- OLDENBORG, P-A. et al., "Role of CD47 as a Marker of Self on Red Blood Cells", Science, (20000000), vol. 288, no. 5473, pages 2051 - 2054, XP055304810
OPPOSITION- OLDENBORG, P-A., "CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease", ISRN Hematology, (20130000), vol. 2013, pages 1 - 19, XP055663144
OPPOSITION- PETROVA, P. S. et al., "TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding", Clin. Cancer Res., (20170000), vol. 23, no. 4, pages 1068 - 1079, XP055540513
OPPOSITION- OLDENBORG, P-A., "Role of CD47 and Signal Regulatory Protein Alpha (SIRPa) in Regulating the Clearance of Viable or Aged Blood Cells", Transfus. Med. 6t Hemother, (20120000), vol. 39, no. 5, pages 315 - 320, XP055663208
OPPOSITION- OLSSON, M. et al., "Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia", Blood, (20050000), vol. 105, no. 9, pages 3577 - 3482, XP055347748
OPPOSITION- METZELER, K. H. et al., "An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia", Blood, (20080000), vol. 112, pages 4193 - 4201, XP055007850
OPPOSITION- BURGER, P. et al., "CD47 functions as a molecular switch for erythrocyte phagocytosis", Blood, (20120000), vol. 119, no. 23, pages 5512 - 5521, XP055663204
OPPOSITION- KAUDER, S., E. et al., "ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile", PLOS one, (20180000), vol. 13, no. 8, pages 1 - 33, XP055635503
OPPOSITION- METAYER, L. E. et al., "Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis", Oncotarget, (20170000), vol. 8, no. 37, pages 60892 - 60903, XP055456424
OPPOSITION- LIU, L. et al., "Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells", Frontiers in Immunology, (20170000), vol. 8, no. 404, pages 1 - 16, XP055651389
OPPOSITION- UNO, S. et al., "Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia", Oncol. Rep., (20070000), vol. 17, pages 1189 - 1194, XP055127957
SEARCH- SZENAJCH J ET AL, "The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1806, no. 1, ISSN 0304-419X, (20100801), pages 82 - 95, (20100609), XP027083746 [Y] 1-14 * page 83, column l, paragraph 1 - column r, paragraph 3 *
SEARCH- S. B. WILLINGHAM ET AL, "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20120326), vol. 109, no. 17, doi:10.1073/pnas.1121623109, ISSN 0027-8424, pages 6662 - 6667, XP055302774 [Y] 1-14 * abstract * * page 6666, column l, paragraph 1 - paragraph 3; figure S6 * * page 6666, column r, paragraph l *
SEARCH- OLDENBORG P-A, "ROLE OF CD47 IN ERYTHROID CELLS AND IN AUTOIMMUNITY", LEUKEMIA AND LYMPHOMA, INFORMA HEALTHCARE, US, (20040701), vol. 45, no. 7, doi:10.1080/1042819042000201989, ISSN 1042-8194, pages 1319 - 1327, XP008060559 [Y] 1-14 * page 1324, column r, paragraph l - page 1325, column r, paragraph 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents